Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2- Metastatic Breast Cancer: A Podcast

被引:0
|
作者
Dong, Brian [1 ]
Lusen, Rita [2 ]
Chick, Ella [2 ]
Kline, Lisa [2 ]
机构
[1] Univ Louisville Hlth, Brown Canc Ctr, 529 Jackson St, Louisville, KY 40202 USA
[2] Breastcancer Org, Ardmore, PA USA
关键词
Cyclin-dependent kinase 4/6 inhibitor; HR+/HER2; metastatic breast cancer; Shared decision-making; HEALTH LITERACY; INFORMATION;
D O I
10.1007/s40487-023-00237-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Shared decision-making involves patients engaging with their physicians to make informed decisions regarding treatment selection, a process that empowers patients and ensures that treatment decisions reflect their individual values and preferences. However, shared decision-making can be challenging to implement for various reasons, including time, staffing, or resource limitations at community practices and differences in patients' cultural backgrounds or health literacy. In this podcast, we discuss how to ensure that individual patients' needs and concerns are addressed, including an overview of different approaches for initial consultations, strategies for tailoring conversations based on a patient's background or health literacy, and trustworthy resources that can help improve patients' understanding. As an illustrative example, we focus on how to implement shared decision-making to address the needs of a patient with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer who is eligible for combination therapy with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor. Overall, this podcast illustrates how shared decision-making is an achievable goal, even in small or underresourced practices, and provides an instructive guide on how to facilitate shared decisionmaking for patients with HR+/HER2- metastatic breast cancer.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [1] Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast
    Brian Dong
    Rita Lusen
    Ella Chick
    Lisa Kline
    Oncology and Therapy, 2023, 11 : 411 - 418
  • [2] Locoregional Management Based on Mode of Progression for HR+/HER2-metastatic breast cancer Treated with Combined CDK4/6 inhibitor with Aromatase inhibitor
    Redfern, Andrew
    Law, Ngie
    Weerasena, Indunil
    Spalding, Lisa
    Martin, Hilary
    CANCER RESEARCH, 2024, 84 (09)
  • [3] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [4] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [5] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [6] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [7] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [8] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
    Rugo, Hope S.
    Brufsky, Adam
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Layman, Rachel M.
    Cristofanilli, Massimo
    Torres, Mylin A.
    Curigliano, Giuseppe
    Finn, Richard S.
    DeMichele, Angela
    NPJ BREAST CANCER, 2022, 8 (01)
  • [9] MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
    Dickler, Maura N.
    Tolaney, Sara M.
    Rugo, Hope S.
    Cortes, Javier
    Dieras, Veronique
    Patt, Debra
    Wildiers, Hans
    Hudis, Clifford A.
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Frenzel, Martin
    Koustenis, Andrew
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5218 - 5224
  • [10] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406